Comparison of therapeutic effects of prednisone combined with mycophenolate mofetil versus cyclosporin A in children with steroid-resistant nephrotic syndrome.
- Author:
Zhi-Hui LI
1
,
2
;
Zhi LIN
;
Cui-Rong DUAN
;
Tian-Hui WU
;
Mai XUN
;
Yi ZHANG
;
Liang ZHANG
;
Yun-Feng DING
;
Yan YIN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Child; Child, Preschool; Cyclosporine; administration & dosage; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; administration & dosage; Infant; Male; Mycophenolic Acid; administration & dosage; analogs & derivatives; Nephrotic Syndrome; drug therapy; Prednisone; administration & dosage; Retrospective Studies; Treatment Outcome
- From: Chinese Journal of Contemporary Pediatrics 2016;18(2):130-135
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the therapeutic effects of prednisone combined with mycophenolate mofetil (MMF) versus cyclosporin A (CsA) in children with steroid-resistant nephrotic syndrome (SRNS).
METHODSThe clinical data of 164 SRNS children who were treated with prednisone combined with MMF or CsA between January 2004 and December 2013 were collected, and the clinical effect of prednisone combined with MMF (MMF group, 112 children) or CsA (CsA group, 52 children) was analyzed retrospectively.
RESULTSAt 1 month after treatment, the CsA group had a significantly higher remission rate than the MMF group (67.3% vs 42.9%; P<0.05). At 3 months after treatment, the CsA group also had a significantly higher remission rate than the MMF group (78.8% vs 63.3%; P<0.05). The 24-hour urinary protein excretion in both groups changed significantly with time (P<0.05) and differed significantly between the two groups (P<0.05). There were no serious adverse events in the two groups.
CONCLUSIONSPrednisone combined with MMF or CsA is effective and safe for the treatment of SRNS in children, and within 3 months of treatment, CsA has a better effect than MMF.
